Should I buy AdaptHealth Corp. (AHCO) stock or is it too late?
⭐ The most reliable of them, either direction: Jefferies — 61% of its targets hit on this sector (137 calls tested). It aims for $13 (+105 %), call made on July 22, 2026, maturing on July 22, 2027 (84 d ago).
Firm-by-firm track record on AdaptHealth Corp.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| SVB Leerink | 45 % | +15.7 % | 11 | $30 +374% |
| UBS | 60 % | +6.1 % | 5 | $10 +58% |
| RBC Capital | 50 % | +5.2 % | 10 | $8 +26% |
| Truist Securities | 33 % | -7.9 % | 12 | $9 +42% |
| Canaccord Genuity | 14 % | -14.8 % | 7 | $16 +153% |
| Baird | 0 % | -18.2 % | 9 | $9 +42% |
✅ Reasons to believe
- 100% of analysts rate it a buy (Buy consensus, 6 ratings) — a sign of market conviction.
- Median price target $10, i.e. +50% from the current price ($6).
- The most reliable firm on AHCO, UBS (60% hit rate, 5 scored calls), targets $10 (call made on August 6, 2026, maturing on August 6, 2027) (+58%) in its most recent call, and $14 (call made on May 6, 2026, maturing on May 6, 2027) (+121%) in the one coming due soonest.
⚠️ Reasons to hesitate
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
- A near-unanimous consensus leaves little room for positive surprise — a lot of optimism is already baked in.
The analyst consensus on AHCO
Median target $10 (+50%) · 6 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in AdaptHealth Corp. now?
We won't decide for you. The facts: 100% of analysts rate it a buy, median target $10 (+50%), and UBS (most reliable on AHCO, 60%) targets $10. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in AdaptHealth Corp.?
Not according to analysts: the median target ($10) is still +50% above the current price ($6) (most reliable on AHCO: UBS, 60%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is AdaptHealth Corp. still worth investing in?
It depends on the gap between the price ($6) and its estimated value: analysts target $10 on median (+50%), with 100% buys (most reliable on AHCO: UBS, 60%). Cross-check with their real reliability on AHCO and the cautions above. Information, not advice.
What's the main risk in buying AHCO?
A 12-month target is not a guaranteed path: the price can fall in the meantime.
→ Go deeper: the full AdaptHealth Corp. profile (consensus, analyst reliability, price target, performance).